Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases and vaccines for infectious diseases. The company operates two proprietary platform technologies: STARR, a self-amplifying mRNA technology, and LUNAR, a lipid nanoparticle delivery system. Its product portfolio includes KOSTAIVE, an approved sa-mRNA vaccine against COVID-19, and clinical-stage RNA therapeutic candidates ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 for cystic fibrosis. Arcturus partners with CSL Seqirus for the development and commercialization of mRNA vaccines for COVID-19, influenza, and other infectious diseases, with Meiji Seika Pharma serving as the exclusive commercialization partner in Japan. The company serves markets in Japan, the European Union, and the United Kingdom, where KOSTAIVE has received regulatory approval. Clinical trials for its rare disease therapeutics are conducted in collaboration with regulatory agencies including the U.S. FDA and the European Medicines Agency.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage arcturusrx.com
Sector Healthcare IR page ir.arcturusrx.com
Tags
mrna therapeutics, rare diseases, cystic fibrosis, ornithine transcarbamylase deficiency, vaccines, lipid nanoparticles, self-amplifying mrna, infectious diseases, gene therapy, KOSTAIVE, STARR, LUNAR, ARCT-810, ARCT-032, ARCT-154, ARCT-2301, ARCT-2303, CSL Seqirus, Meiji Seika Pharma, ATX
Press page —

Metrics

Valuation  
Market cap $ 389.631M
Market cap (USD) $ 389.631M
P/E -4.42
PEG —
P/BV 2.31
P/S 12.77
P/OCF -6.24
P/FCF -6.24
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.9%
ROI -1,704.2%
ROIC -1,481.7%
Profit margin -80.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 25
Quality score -72.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 82.031M 152.31M 166.799M 205.999M 12.359M 9.539M 20.789M 15.753M
Net profit -65.783M -80.941M -29.725M 9.349M -203.674M -72.148M -25.991M -21.785M
Free cash flow -74.501M -60.395M -21M 24.267M -138.449M -44.603M -7.263M -22.238M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 6.13 16.97 31.53 16.96 37.01 43.38 10.87 —
Price performance 12m -0.64 -0.46 0.86 -0.54 -0.15 2.99 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 4.48M 2.18M 2.13M 3.37M 2.76M 32.1M 3.97M 5.56M
↳ YoY growth -51.4% -2.5% +58.4% -17.9% +1,060.1% -87.6% +40.0%
↳ 5y CAGR +48.2% +12.8% +21.2%
Borrowings, current (USD) — — — 1.25M 22.5M 60.7M — — —
Borrowings, non-current (USD) — 9.91M 15M 13.8M 40.6M — — — —
Lease liabilities (USD) — — 5.68M 5.66M 6.04M 34.1M 30.2M 28.6M 25M
Cash and deposits (USD) 25.2M 36.7M 71.4M 463M 370M 392M 292M 237M 231M
Right-of-use assets (USD) — — 5.13M 5.18M 5.62M 32.5M 28.5M 26.7M 21.1M
Net debt (borrowings + leases - cash) (USD) — -26.8M -50.7M -442M -301M -297M — — —
Cash flow detail
Operating cash flow (USD) — -20.8M -6.45M -42.9M -135M 32M -18.1M -59.7M -74.3M
Purchases of property, plant and equipment (USD) — -1.48M -818,000 -1.74M -3.41M -7.73M -2.9M -648,000 -230,000
Change in receivables (cash effect) (USD) — -4M 2.3M 54,000 -1.24M 603,000 -29.3M 28.1M -1.59M
Change in payables (cash effect) (USD) — 578,000 3.16M 4.81M -769,000 -3.11M -2.24M 1.92M -2.96M
Interest paid (cash effect) (USD) — -146,000 -691,000 -751,000 -684,000 -813,000 -2.13M — —
Income taxes paid (cash effect) (USD) — — — — — — — -1.41M —
Share-based compensation (USD) — 1.26M 1.98M 6.76M 28.9M 30.6M 34.6M 38M 25.4M
Operating cash flow before change in receivables (USD) — -16.8M -8.75M -42.9M -134M 31.4M 11.2M -87.8M -72.7M
Free cash flow (OCF - PPE - intangibles) (USD) — -22.2M -7.26M -44.6M -138M 24.3M -21M -60.4M -74.5M
Income detail
Research and development expense (USD) — 17M 33.6M 57.8M 174M 148M 192M 195M 112M
↳ 5y CAGR +62.5% +42.1% +14.2%
Total comprehensive income (USD) — -21.8M -26M -72.1M -204M 9.35M -29.7M -80.9M -65.8M
Comprehensive income to owners (USD) — -21.8M -26M -72.1M -204M 9.35M -29.7M -80.9M -65.8M
Reported Aug 14, 2019 Mar 16, 2020 Mar 16, 2020 Mar 1, 2021 Mar 1, 2022 Mar 29, 2023 Mar 14, 2024 Mar 6, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

$50 Million Strategic Investment in Arcturus at an 80% Premium

Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform

SAN DIEGO--(BUSINESS WIRE) -- November 16, 2026 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. (“Meiji”), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding (“MOU”) related to pandemic preparedness and response in Japan and an exclusive license relating to the application of Arcturus’ ARCT-154 technology for an undisclosed therapeutic area.

Under the terms of the securities purchase agreement, Meiji will purchase $50 million of unregistered Arcturus securities at a purchase price of $20.27 per share, which is 7.9% of the outstanding shares of Arcturus after the transaction.

ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027

ARCT-2601 (OTC Deficiency), the first mRNA therapeutic candidate utilizing LUNAR 2.0™, Phase 2 dosing planned to begin Q1 2027; top-line data H2 2027

Investor conference call at 4:30 p.m. ET today

SAN DIEGO--(BUSINESS WIRE) -- November 5, 2026 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced its financial results for the quarter ended September 30, 2026, and provided corporate updates.

“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates,” said Joseph Payne, President & CEO of Arcturus.

October 26, 2026 at 4:01 PM EDT

PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5th and will also host a conference call and webcast at 4:30 pm Eastern Time on November 5, 2026.

Arcturus Therapeutics Third Quarter 2026 Earnings Conference Call

  • Thursday, November 5, 2026, at 4:30 p.m. ET

  • Domestic: 1-800-225-9448

  • International: 1-203-518-9708

  • Conference ID: ARCTURUS

  • Webcast: Link

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus’ strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261026684656/en/

Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 [email protected]

Source: Arcturus Therapeutics Holdings Inc.

ArabicChineseDanishDutchEnglishEspañolFinnishFrenchGermanHebrewHungarianHindiItalianJapaneseKoreanMalayNorwegianSwedishSerbian LatinSerbian CirillicPolishPortugueseTamil

Accessibility Menu

Choose a Safe Browsing Profile

Active

ONOFF

Color Blindness Adjustments

Color adjustment for colorblind users

Selecting a color profile below will make the screen colors more distinct for each profile type.

Red-green color blindness

Deuteranomaly

Protanomaly

Protanopia

Deuteranopia

Blue-yellow color blindness

Tritanopia

Tritanomaly

Other color blindness

Achromatopsia

Achromatomaly

ONOFF

Seizure Safe Mode

Reduces saturation and stops animations

This mode reduces the risk of seizure that result from flashing or blinking animations and risky color combinations by reducing saturation and stopping animations, transitions, and videos.

ONOFF

Visually Impaired Mode

Adjusts screen to assist with visual elements

This mode adjusts visual elements on the screen to assist users with visual impairment

ONOFF

Cognitive Disability Mode

Improves identification of elements.

This mode provides assistive highlighting of titles and links to allow users with cognitive disabilities to identify and navigate page elements.

ONOFF

ADHD/Focus Friendly Mode

Reduces distractions and improves focus

This mode reduces distractions to help users with ADHD and Neurodevelopmental disorders to read, browse, and focus content much easier.

ONOFF

Assistive Navigation Mode

Enables keyboard navigation with screen reader

This mode allows keyboard navigation throughout the page, and includes a screen reader for assistive navigation

Content Control

Readable Font

Dyslexia Font

Highlight Titles

Highlight Links

Text Magnifier

Content Scaling

Reset

Font Size

Reset

Line Height

Reset

Letter Spacing

Reset

Align Left

Align Center

Align Right

Design Control

Dark Contrast

Invert Colors

Light Contrast

Monochrome

High Contrast

High Saturation

Low Saturation

Adjust Text Colors

Remove

Adjust Title Colors

Remove

Adjust Background Colors

Remove

Orientation Control

Mute Sounds

Hide Images

Reading Guide

Stop Animations

Reading Mask

Highlight on Hover

Highlight on Click

Large Cursor

Screen Reader

Keyboard Navigation

Website Accessibility by Website Accessibility by AllAccessible

Accessibility Statement

We are committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards and best practices regularly.

Conformance status

The Web Content Accessibility Guidelines (WCAG) define requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA.

We have installed an automatic accessibility tool that runs in the background. This tool runs Ai and machine learning to remediate accessibility deficiencies in the HTML code. In addition, it provides an interface that allows visitors to manipulate their browsing experience. The complete toolset aims to assist this site in conforming as closely as possible to the standards by the WCAG 2.1 Level AA.

Additional accessibility considerations

Although our goal is WCAG 2.1 Level AA conformance, we have also applied some Level AAA Success Criteria: Images of text are only used for decorative purposes. Some WCAG 2.1 Level AA requirements are not included in the remediation process as they are outside of the scope of the website source code, including but not limited to video captions.

Measures taken by this website to achieve compliance

  • Complete WCAG 2.1 Level AA website audit and remediation on page load. All on-page elements are scanned and reviewed against our accessibility standards library to ensure compliance. If remediation is required, the element is tagged, and our Ai remediation tool makes necessary, non-invasive corrections on the client-side of the site

  • Auto Image and Link recognition and remediation for content that does not contain alt or title text for users that require screen reader access; descriptions are stored for user adjustment to assist our machine learning algorithms

  • Quick access to search Meriam Website for definitions and pronunciations of words.

  • Colorblindness adjustments to improve distinction between colors for Red-green color blindness (Deuteranomaly, Protanomaly, Protanopia, Deuteranopia), Blue-yellow color blindness (Tritanopia, Tritanomaly), Other color blindness (Achromatopsia, Achromatomaly)

  • Reset fonts to Arial or Implementation of Dyslexia friendly font

  • Ability to Highlight Titles and Links

  • Text Magnification

  • Content, Font, Line Height, Line Spacing Scaling, and Zoom

  • Content alignment including left, center, and right

  • Dark and Light Contrast modes and High Contrast that increases contrast ratio to 135%, and complete inversion of colors

  • Saturation adjustments including High (140% saturation), Low (90% saturation), Monochrome (0% saturation)

  • Complete element color control including Title, Font, and background color adjustments with color-safe color palettes to ensure optimal contrast ratio of 4.5%

  • Ability to stop motion (videos, animated graphics, web element transitions, etc.), hide all images, and mute sounds

  • Simple reading guide or more elaborate page mask to assist users in focusing on-page content

  • Highlight element on hover or focus to ensure both keyboard and mouse users can orient themselves on the focused element

  • A screen reader that reads back page content on highlight

  • Complete keyboard navigation control

  • Aggregated settings into browsing profiles to quickly deploy accessibility configurations for multiple user types.

Compatibility with browsers and assistive technology

We strive to be compatible with the following assistive technologies:

  • Google Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS, and NVDA (screen readers), both for Windows and for MAC users.

Technical specifications

Accessibility of this site relies on the following technologies to work with the particular combination of web browsers and any assistive technologies or plugins installed on your computer:

  • HTML

  • WAI-ARIA

  • CSS

  • JavaScript

These technologies are relied upon for conformance with the accessibility standards used.

Notes

While our main goal is to make the entire site accessible to all users, there is a possibility that some pages may not have been discovered or do not have a satisfactory accessibility remediation solution at this time. We are committed to constantly improving the accessibility of this site to ensure it is accessible to all.

Move or Hide the Accessibility Panel

Hide Accessility WidgetHide for 1 DayHide for 1 WeekHide for 1 MonthHide for 1 YearSelect a length of time to hide the accessibility widget. If you wish to show the widget before this period ends, you will need to clear your site cookies.Confirm and Hide

Page Link Tree

Page Landmarks
  • Region

  • Banner

  • Navigation

  • Main

  • Complementary

  • Navigation

  • Navigation

  • Navigation

  • Navigation

  • Navigation

  • Navigation

  • Contentinfo

  • Navigation

Page Links

Prompts

Arcturus Therapeutics Holdings Inc. (ticker ARCT), listed in United States.

ETFs Holding Arcturus Therapeutics Holdings Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.39% 3,174,891 $ 25.304M Nov 18, 2026
NXTE 0.18% 15,609 $ 104.892K Jun 30, 2026
RUSC 0.14% 16,752 $ 112.573K Jun 30, 2026
AVSC 0.02% 59,712 $ 496.207K Nov 16, 2026
DFAS 0.00% 48,797 $ 411.847K Nov 12, 2026
DXUV 0.00% 4,638 $ 39.145K Nov 12, 2026
DFAC 0.00% 34,519 $ 291.34K Nov 12, 2026
DFAU 0.00% 3,894 $ 32.865K Nov 12, 2026
DCOR 0.00% 7,848 $ 66.237K Nov 12, 2026
AVUS 0.00% 6,635 $ 55.137K Nov 16, 2026